Navigation Links
Medivation to Host Conference Call at 8:30 a.m. Eastern Time Tomorrow to Discuss Partnering Plans for MDV3100
Date:10/26/2009

SAN FRANCISCO, Oct. 26 /PRNewswire-FirstCall/ -- Medivation, Inc. (Nasdaq: MDVN) today announced that it will hold a teleconference at 8:30 a.m. Eastern Time tomorrow, Tuesday, October 27, to discuss partnering plans for MDV3100, Medivation's investigational drug which is currently in Phase 3 testing for the treatment of prostate cancer.

Teleconference/Webcast Details

To participate in the live call on Tuesday, October 27, at 8:30 a.m. Eastern Time (5:30 a.m. Pacific Time), please dial 888-280-4443 for domestic callers and 1-719-457-2638 for international callers. Individuals interested in listening to the live call via webcast may do so by visiting http://www.medivation.com.

About Medivation

Medivation, Inc. is a biopharmaceutical company focused on the rapid development of novel small molecule drugs to treat serious diseases for which there are limited treatment options. Medivation aims to transform the treatment of these diseases and offer hope to critically ill patients and their caregivers. In September 2008, Medivation announced a global agreement with Pfizer Inc to develop and commercialize dimebon (latrepirdine) for the treatment of Alzheimer's and Huntington diseases. With Pfizer, Medivation is conducting a broad dimebon clinical development program that includes several Phase 3 trials assessing the efficacy and safety of dimebon taken alone or in combination with other Alzheimer's medications in patients with mild, moderate and severe Alzheimer's disease. The companies are also conducting a Phase 3 trial of dimebon in Huntington disease. A Phase 3 clinical trial of MDV3100 in patients with castration-resistant prostate cancer is under way. For more information, please visit us at http://www.medivation.com.

SOURCE Medivation


'/>"/>
SOURCE Medivation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Medivation Announces Participation in Upcoming Conferences
2. Medivation Completes Enrollment in Confirmatory, Pivotal Phase 3 CONNECTION Trial of Dimebon in Patients With Alzheimers Disease
3. Medivation Announces Pricing of Public Offering
4. Medivation Announces First Quarter 2009 Financial Results Teleconference and Webcast on May 11, 2009
5. Medivation Announces Upcoming Scientific Presentations at Medical Conferences
6. Medivation Reports Fourth Quarter and Year-End 2008 Financial Results and Provides Corporate Update
7. Medivation Announces New Positive Efficacy Data From Phase 1-2 Trial of MDV3100 in Castration-Resistant Prostate Cancer Patients
8. Medivation Presents New Data on Dimebons Novel Mechanism of Action
9. Medivation Announces Participation in RBC Capital Markets 2008 Healthcare Conference
10. Medivation Reports Third Quarter 2008 Financial Results and Provides Corporate Update
11. Medivation Announces Third Quarter 2008 Teleconference and Webcast on November 10, 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2014)... The Workgroup for Electronic Data Interchange ... of health IT to create efficiencies in healthcare information ... Workgroup has developed an issue brief titled, “What ... The HPID Workgroup, a part of WEDI’s Strategic National ... Medicare and Medicaid Services (CMS) to identify common misuse ...
(Date:7/28/2014)... TORONTO , July 28, 2014 /PRNewswire/ -   ... latest group of companies to join its growing portfolio ... hallmarks of Toronto,s JOLT accelerator, ... startups on the roster. Since its ... that have successfully raised  $7.5M of financing. Now at ...
(Date:7/28/2014)... 2014 Appistry, Inc. , a ... the power of genomics to next-generation medicine, announced today ... Challenge . , Two Appistry staff will be ... Center for Genome Resources, and Mr. Neil Miller, director ... Kansas City. Rounding out the panel are Appistry’s Dr. ...
(Date:7/28/2014)... , July 28, 2014 Research and ... Particle Size Analysis Market 2014-2018" report to their offering. ... Particle size analysis is a technique used to determine the ... or liquid. It is crucial to analyze the size of ... Therefore, particle size analysis is performed to determine the behavior ...
Breaking Biology Technology:WEDI’s HPID Workgroup Announces Release of Issue Brief: “What is the Difference Between a Health Plan and Payer?” 2JOLT Announces the Next 6 Startups to Join its Summer 2014 Cohort 2JOLT Announces the Next 6 Startups to Join its Summer 2014 Cohort 3Appistry Names Industry Experts from the National Center for Genome Resources and Mercy Children's, Kansas City, to Judge Pipeline Challenge Competition 2Global Particle Size Analysis Market 2014-2018 2
... Molecular Origami is ... help illustrate the basics of DNA origami, Harvard’s Wyss Institute has created a Flash-based interactive ... a DNA molecule and then allowing it to self assemble. , ... Boston, Mass. (PRWEB) January 28, 2010 -- Molecular ...
... world,s most powerful supercomputers, scientists at Lawrence Berkeley ... a good match for the future development of ... for green energy production because of their ability ... on "Franklin," a Cray XT4 massively parallel processing ...
... PRINCETON, N.J. , Jan. 27 Covance Inc. (NYSE: ... December 31, 2009 of $0.64 per diluted share.  For ... basis, inclusive of $0.10 per share in gains related to ... in the third quarter.  Excluding the gains on sales and the tax ...
Cached Biology Technology:Wyss Institute Launches "Molecular Origami" Interactive Feature 2Wyss Institute Launches "Molecular Origami" Interactive Feature 3Mismatched alloys are a good match for thermoelectrics 2Mismatched alloys are a good match for thermoelectrics 3Covance Reports Fourth Quarter Revenue of $485M and EPS of $0.64 Per Share 2Covance Reports Fourth Quarter Revenue of $485M and EPS of $0.64 Per Share 3Covance Reports Fourth Quarter Revenue of $485M and EPS of $0.64 Per Share 4Covance Reports Fourth Quarter Revenue of $485M and EPS of $0.64 Per Share 5Covance Reports Fourth Quarter Revenue of $485M and EPS of $0.64 Per Share 6Covance Reports Fourth Quarter Revenue of $485M and EPS of $0.64 Per Share 7Covance Reports Fourth Quarter Revenue of $485M and EPS of $0.64 Per Share 8Covance Reports Fourth Quarter Revenue of $485M and EPS of $0.64 Per Share 9Covance Reports Fourth Quarter Revenue of $485M and EPS of $0.64 Per Share 10Covance Reports Fourth Quarter Revenue of $485M and EPS of $0.64 Per Share 11Covance Reports Fourth Quarter Revenue of $485M and EPS of $0.64 Per Share 12Covance Reports Fourth Quarter Revenue of $485M and EPS of $0.64 Per Share 13Covance Reports Fourth Quarter Revenue of $485M and EPS of $0.64 Per Share 14Covance Reports Fourth Quarter Revenue of $485M and EPS of $0.64 Per Share 15Covance Reports Fourth Quarter Revenue of $485M and EPS of $0.64 Per Share 16Covance Reports Fourth Quarter Revenue of $485M and EPS of $0.64 Per Share 17
(Date:7/28/2014)... connections in prairie dogs have uncovered relationships that ... dog communities that may help limit the spread ... The work was done by researchers from North ... Center (NESCent). , "Prairie dogs are increasingly rare ... Jennifer Verdolin, lead author of a paper on ...
(Date:7/27/2014)... to date, researchers from the U.K. provide national, regional, ... virus (HCV). Findings published in Hepatology, a journal of ... indicate that genotype 1 is the most prevalent worldwide, ... reside in East Asia. Genotype 3, at just over ... by genotypes 2, 4, 6, and 5. , ...
(Date:7/27/2014)... scientists at Barts Cancer Institute have found that targeting ... significantly more effective, according to research published in ... Institute, part of Queen Mary University of London, have ... signals the body to repair itself after chemotherapy or ... the researchers removed FAK from blood vessels that grew ...
Breaking Biology News(10 mins):Social network research may boost prairie dog conservation efforts 2Hepatitis C virus genotype 1 is most prevalent worldwide 2New drug target can break down cancer's barrier against treatment 2
... (Cincinnati, OH) In a study published today in the ... an international team of researchers based in the U.S. and ... lethal, breath holding episodes associated with the neurological disease Rett ... that affects around 1 in 10,000 young girls. On October ...
... Institute in Boston have identified a new type of cell ... animal,s own cells from immune system attack. This ... drive lupus and other autoimmune diseases in which the immune ... The discovery, published in the September 16 issue of ...
... October 4, 2010 Onconova Therapeutics, Inc. announced ... regarding a Special Protocol Assessment (SPA) for the design ... 01910.Na) as monotherapy in patients with myelodysplastic syndromes (MDS), ... the bone marrow. The SPA provides FDA evaluation and ...
Cached Biology News:Research breakthrough hailed on the anniversary of gene discovery 2Discovery of a cell that suppresses the immune system 2Onconova announces FDA agreement of a SPA for a pivotal phase 3 trial of Estybon in MDS 2
... 2D polyacrylamide gel electrophoresis (2D-PAGE) with biological ... core technology platform for proteomic analysis. 2D-PAGE ... samples limited only in the dynamic range ... proteins. Quantitative image based analysis of separated ...
... is ideal for high-fidelity amplification of ... as cloning and mutagenesis. High ... enzyme preparation containing recombinant DNA polymerase ... Site5' exonuclease) activity. Platinum Anti-Pfx ...
... PLAU N-term Antibody This antibody is generated ... synthetic peptide selected within aa 50~150 of ... in PBS with 0.09% (W/V) sodium azide. ... G column and eluted out with both ...
...
Biology Products: